SCHEMBL7895151

SCHEMBL7895151

CCC(C(N)=O)c1c[nH]c2c(Cl)c(Cl)ccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 4/20 0.46
CSNK2A2 P19784 3/20 0.46
CSNK2B P67870 3/20 0.46
TNF P01375 2/20 0.36
HAT1 O14929 1/20 0.35
EP300 Q09472 1/20 0.35
IDO1 P14902 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
NR4A2 P43354 1/20 0.33
PKM P14618 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
LIN28A Q9H9Z2 1/20 0.31
PARP14 Q460N5 1/20 0.30
HTR1D P28221 1/20 0.30
CDC7 O00311 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29003665 0.77 BRPF1 (0.49) ALDH1A1LMNAHTTNR4A2PARP14
SCHEMBL7890292 0.76 NR4A2 (0.47) ALDH1A1NR4A2
SCHEMBL1972827 0.71 GPR84 (0.59) ALDH1A1LMNAPKML3MBTL1
SCHEMBL29003653 0.71 NR4A2 (0.46) ALDH1A1LMNANR4A2PKML3MBTL1
SCHEMBL29003630 0.70 TDO2 (0.44) IDO1
SCHEMBL29003655 0.69 RAB9A (0.49) ALDH1A1LMNAHTTNR4A2HTR1D
SCHEMBL2032138 0.68 KCNQ2 (0.48) ALDH1A1
SCHEMBL9235264 0.68 GABRA1 (0.47) NR4A2
SCHEMBL2405000 0.68 MPO (0.51)
SCHEMBL29003613 0.66 HTR2B (0.59) ALDH1A1LMNANR4A2HTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6180657-B1 SLEEP DISORDERS ELI LILLY AND COMPANY 2001-01-30 US disclosed
WO-1997000069-A1 MELATONIN AGONISTS FOR TREATING BENIGN PROSTATIC HYPERPLASIA ELI LILLY AND COMPANY (US) 1997-01-03 WO disclosed